Suven Life Sciences has been granted seven products patents, two from Canada, three from India and one from Eurasia and Japan each corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative disease and these patents are valid throughout 2023, 2024 and 2025.
With these new patents, the company now has total of five granted patents from Canada, thirteen granted patents from India, nine granted patents from Eurasia and finally four granted from Japan for the NCE. These granted patents are exclusive intellectual property of the company are achieved through the internal discovery research efforts. However, products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.
With these new patents, the company now has total of five granted patents from Canada, thirteen granted patents from India, nine granted patents from Eurasia and finally four granted from Japan for the NCE. These granted patents are exclusive intellectual property of the company are achieved through the internal discovery research efforts. However, products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.
No comments:
Post a Comment